Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01468649 · ClinicalTrials.gov registry record · Early Phase 1

Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer

A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.

Completed
Registry status
Early Phase 1
Development phase
50
Enrollment target

NCT01468649 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01468649, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.

COMPLETED
Registry status
Early Phase 1
Development phase
50 participants
Enrollment target

Study Summary

The objective of this Phase II study is to assess the diagnostic accuracy of sentinel lymph node (SLN) identification in patients with breast cancer using near-infrared (NIR) fluorescence optical imaging.

Interventions

  • DEVICE NIR Imaging with FLARE and Mini-FLARE Imaging System

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2011-06
Est. Completion 2013-12
Phase Early Phase 1

What the Registry Record Tells You About NCT01468649

The ClinicalTrials.gov registry entry for NCT01468649 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NIR Imaging with FLARE and Mini-FLARE Imaging System is the first listed.

NCT01468649 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01468649 about?

NCT01468649 is a clinical study titled "Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer". The objective of this Phase II study is to assess the diagnostic accuracy of sentinel lymph node (SLN) identification in patients with breast cancer using near-infrared (NIR) fluorescence optical imaging.

What is the current status of trial NCT01468649?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2011-06. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01468649?

The interventions under investigation include: NIR Imaging with FLARE and Mini-FLARE Imaging System (DEVICE).

Who is sponsoring clinical trial NCT01468649?

This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.